Immunomedics nets $2.1M in NIH grants
Immunomedics has been awarded three grants by the National Institutes of Health (NIH), totaling $2.1 million payable over a period of two years.
The NIH awarded Morris Plains, N.J.-based Immunomedics two multi-year phase II grants. One was for the development of F18-labeled peptides for pretargeted PET imaging of pancreatic cancer and another to support a combined radio- and immunotherapy agent for aggressive non-Hodgkin's lymphoma (NHL).
The company also was awarded a phase I grant for the development of a hematopoietic tumor-targeting humanized antibody conjugated with interferon-a2b groups.
The NIH awarded Morris Plains, N.J.-based Immunomedics two multi-year phase II grants. One was for the development of F18-labeled peptides for pretargeted PET imaging of pancreatic cancer and another to support a combined radio- and immunotherapy agent for aggressive non-Hodgkin's lymphoma (NHL).
The company also was awarded a phase I grant for the development of a hematopoietic tumor-targeting humanized antibody conjugated with interferon-a2b groups.